Verastem, Inc.
VSTMHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Headquartered within the healthcare sector, Verastem, Inc. focuses on Biotechnology services and products. Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Valued at $377.0M, VSTM is a small-cap name in its sector. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Market Cap
$377.0M
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
-3.60
EPS (TTM)
$-2.52
EPS (Fwd)
$-1.19
ROE
-786.2%
ROA
-59.4%
Cash
$181.7M
Total Debt
$85.5M
Free CF
-$92.7M
52W Change
-43.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $181.7M in cash comfortably exceeding the $85.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$92.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -786.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.6M (2022) to $30.9M (2025), reflecting a 1091% increase over the period.
With a beta below 0.7, Verastem, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, VSTM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Verastem, Inc.'s trajectory.